Prolonged overall survival with second on‐demand autologous transplant in multiple myeloma
Between August 1993 and March 2003, 130 consecutive multiple myeloma (MM) patients eligible for high‐dose treatment were offered a program including up‐front autologous stem cell transplantation (ASCT) after conditioning with 200 mg/m2 melphalan followed by a second ASCT in case of relapse or progre...
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 2006-06, Vol.81 (6), p.426-431 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 431 |
|---|---|
| container_issue | 6 |
| container_start_page | 426 |
| container_title | American journal of hematology |
| container_volume | 81 |
| creator | Elice, Francesca Raimondi, Roberto Tosetto, Alberto D'Emilio, Anna Di Bona, Eros Piccin, Andrea Rodeghiero, Francesco |
| description | Between August 1993 and March 2003, 130 consecutive multiple myeloma (MM) patients eligible for high‐dose treatment were offered a program including up‐front autologous stem cell transplantation (ASCT) after conditioning with 200 mg/m2 melphalan followed by a second ASCT in case of relapse or progression. A total of 107 (82%) patients completed the first ASCT. The best response obtained after ASCT was complete response (CR) 23%, very good partial response (VGPR) 28%, partial response (PR) 42%, and minimal response (MR) 7%. Median overall survival (OS) and event‐free survival (EFS) were 65.4 and 27.7 months, respectively. Relapse or progression occurred in 70 patients; 26 received a second ASCT (with a median time of 20.4 months from first ASCT). A major response (≥PR) was obtained in 69% of these patients. Median OS and EFS after the second ASCT were 38.1 and 14.8 months. Treatment‐related mortality was 1.9% after the first ASCT but no deaths occurred after the second.
Our experience suggests that elective up‐front single ASCT followed by second ASCT after relapse or progression is a safe and effective global strategy to treat MM patients. Am. J. Hematol. 81:426–431, 2006. © 2006 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/ajh.20641 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68039746</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19738078</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4191-1fd48d4bc25b8e2e2a6a1a44b7ce5fb6e605aa2e0d3a551e84ef240a6738daa53</originalsourceid><addsrcrecordid>eNqFkM9Kw0AQhxdRbK0efAHJRcFD2t1ks0mOpahVCnrQmxAmyaRN2fxxN2npzUfwGX0StybQk3iagfn2N7MfIZeMjhmlzgTWq7FDBWdHZMhoKOxAeM4xGVJXMNPTcEDOtF5TyhgP6CkZMCEC6rvekLy_qEpW5RJTq9qgAikt3apNvgFpbfNmZWlMqtIMy-_PrxQLMD20jXmzrFptNQpKXUsoGysvraKVTV5LtIodyqqAc3KSgdR40dcRebu_e53N7cXzw-NsurATzkJmsyzlQcrjxPHiAB10QAADzmM_QS-LBQrqAThIUxc8j2HAMXM4BeG7QQrguSNy0-XWqvpoUTdRkesEpbkLzZWR-awb-lz8C7LQRFI_MOBtByaq0lphFtUqL0DtIkajvfPIOI9-nRv2qg9t4wLTA9lLNsB1D4BOQGbGWZLrA-f7YRjyPTfpuG0ucff3xmj6NO9W_wBgVZre</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19738078</pqid></control><display><type>article</type><title>Prolonged overall survival with second on‐demand autologous transplant in multiple myeloma</title><source>MEDLINE</source><source>Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Elice, Francesca ; Raimondi, Roberto ; Tosetto, Alberto ; D'Emilio, Anna ; Di Bona, Eros ; Piccin, Andrea ; Rodeghiero, Francesco</creator><creatorcontrib>Elice, Francesca ; Raimondi, Roberto ; Tosetto, Alberto ; D'Emilio, Anna ; Di Bona, Eros ; Piccin, Andrea ; Rodeghiero, Francesco</creatorcontrib><description>Between August 1993 and March 2003, 130 consecutive multiple myeloma (MM) patients eligible for high‐dose treatment were offered a program including up‐front autologous stem cell transplantation (ASCT) after conditioning with 200 mg/m2 melphalan followed by a second ASCT in case of relapse or progression. A total of 107 (82%) patients completed the first ASCT. The best response obtained after ASCT was complete response (CR) 23%, very good partial response (VGPR) 28%, partial response (PR) 42%, and minimal response (MR) 7%. Median overall survival (OS) and event‐free survival (EFS) were 65.4 and 27.7 months, respectively. Relapse or progression occurred in 70 patients; 26 received a second ASCT (with a median time of 20.4 months from first ASCT). A major response (≥PR) was obtained in 69% of these patients. Median OS and EFS after the second ASCT were 38.1 and 14.8 months. Treatment‐related mortality was 1.9% after the first ASCT but no deaths occurred after the second.
Our experience suggests that elective up‐front single ASCT followed by second ASCT after relapse or progression is a safe and effective global strategy to treat MM patients. Am. J. Hematol. 81:426–431, 2006. © 2006 Wiley‐Liss, Inc.</description><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.20641</identifier><identifier>PMID: 16680735</identifier><identifier>CODEN: AJHEDD</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; autologous transplant ; Biological and medical sciences ; Disease Progression ; Disease-Free Survival ; Female ; Hematologic and hematopoietic diseases ; Humans ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunopathology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Melphalan - administration & dosage ; Middle Aged ; Multiple Myeloma - mortality ; Multiple Myeloma - therapy ; Myeloablative Agonists - administration & dosage ; myeloma ; Recurrence ; relapse ; Remission Induction ; Retrospective Studies ; Stem Cell Transplantation - mortality ; Survival Rate ; Transplantation Conditioning ; Transplantation, Autologous</subject><ispartof>American journal of hematology, 2006-06, Vol.81 (6), p.426-431</ispartof><rights>Copyright © 2006 Wiley‐Liss, Inc.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4191-1fd48d4bc25b8e2e2a6a1a44b7ce5fb6e605aa2e0d3a551e84ef240a6738daa53</citedby><cites>FETCH-LOGICAL-c4191-1fd48d4bc25b8e2e2a6a1a44b7ce5fb6e605aa2e0d3a551e84ef240a6738daa53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.20641$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.20641$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17799945$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16680735$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Elice, Francesca</creatorcontrib><creatorcontrib>Raimondi, Roberto</creatorcontrib><creatorcontrib>Tosetto, Alberto</creatorcontrib><creatorcontrib>D'Emilio, Anna</creatorcontrib><creatorcontrib>Di Bona, Eros</creatorcontrib><creatorcontrib>Piccin, Andrea</creatorcontrib><creatorcontrib>Rodeghiero, Francesco</creatorcontrib><title>Prolonged overall survival with second on‐demand autologous transplant in multiple myeloma</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><description>Between August 1993 and March 2003, 130 consecutive multiple myeloma (MM) patients eligible for high‐dose treatment were offered a program including up‐front autologous stem cell transplantation (ASCT) after conditioning with 200 mg/m2 melphalan followed by a second ASCT in case of relapse or progression. A total of 107 (82%) patients completed the first ASCT. The best response obtained after ASCT was complete response (CR) 23%, very good partial response (VGPR) 28%, partial response (PR) 42%, and minimal response (MR) 7%. Median overall survival (OS) and event‐free survival (EFS) were 65.4 and 27.7 months, respectively. Relapse or progression occurred in 70 patients; 26 received a second ASCT (with a median time of 20.4 months from first ASCT). A major response (≥PR) was obtained in 69% of these patients. Median OS and EFS after the second ASCT were 38.1 and 14.8 months. Treatment‐related mortality was 1.9% after the first ASCT but no deaths occurred after the second.
Our experience suggests that elective up‐front single ASCT followed by second ASCT after relapse or progression is a safe and effective global strategy to treat MM patients. Am. J. Hematol. 81:426–431, 2006. © 2006 Wiley‐Liss, Inc.</description><subject>Adult</subject><subject>Aged</subject><subject>autologous transplant</subject><subject>Biological and medical sciences</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melphalan - administration & dosage</subject><subject>Middle Aged</subject><subject>Multiple Myeloma - mortality</subject><subject>Multiple Myeloma - therapy</subject><subject>Myeloablative Agonists - administration & dosage</subject><subject>myeloma</subject><subject>Recurrence</subject><subject>relapse</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Stem Cell Transplantation - mortality</subject><subject>Survival Rate</subject><subject>Transplantation Conditioning</subject><subject>Transplantation, Autologous</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM9Kw0AQhxdRbK0efAHJRcFD2t1ks0mOpahVCnrQmxAmyaRN2fxxN2npzUfwGX0StybQk3iagfn2N7MfIZeMjhmlzgTWq7FDBWdHZMhoKOxAeM4xGVJXMNPTcEDOtF5TyhgP6CkZMCEC6rvekLy_qEpW5RJTq9qgAikt3apNvgFpbfNmZWlMqtIMy-_PrxQLMD20jXmzrFptNQpKXUsoGysvraKVTV5LtIodyqqAc3KSgdR40dcRebu_e53N7cXzw-NsurATzkJmsyzlQcrjxPHiAB10QAADzmM_QS-LBQrqAThIUxc8j2HAMXM4BeG7QQrguSNy0-XWqvpoUTdRkesEpbkLzZWR-awb-lz8C7LQRFI_MOBtByaq0lphFtUqL0DtIkajvfPIOI9-nRv2qg9t4wLTA9lLNsB1D4BOQGbGWZLrA-f7YRjyPTfpuG0ucff3xmj6NO9W_wBgVZre</recordid><startdate>200606</startdate><enddate>200606</enddate><creator>Elice, Francesca</creator><creator>Raimondi, Roberto</creator><creator>Tosetto, Alberto</creator><creator>D'Emilio, Anna</creator><creator>Di Bona, Eros</creator><creator>Piccin, Andrea</creator><creator>Rodeghiero, Francesco</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200606</creationdate><title>Prolonged overall survival with second on‐demand autologous transplant in multiple myeloma</title><author>Elice, Francesca ; Raimondi, Roberto ; Tosetto, Alberto ; D'Emilio, Anna ; Di Bona, Eros ; Piccin, Andrea ; Rodeghiero, Francesco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4191-1fd48d4bc25b8e2e2a6a1a44b7ce5fb6e605aa2e0d3a551e84ef240a6738daa53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>autologous transplant</topic><topic>Biological and medical sciences</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melphalan - administration & dosage</topic><topic>Middle Aged</topic><topic>Multiple Myeloma - mortality</topic><topic>Multiple Myeloma - therapy</topic><topic>Myeloablative Agonists - administration & dosage</topic><topic>myeloma</topic><topic>Recurrence</topic><topic>relapse</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Stem Cell Transplantation - mortality</topic><topic>Survival Rate</topic><topic>Transplantation Conditioning</topic><topic>Transplantation, Autologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elice, Francesca</creatorcontrib><creatorcontrib>Raimondi, Roberto</creatorcontrib><creatorcontrib>Tosetto, Alberto</creatorcontrib><creatorcontrib>D'Emilio, Anna</creatorcontrib><creatorcontrib>Di Bona, Eros</creatorcontrib><creatorcontrib>Piccin, Andrea</creatorcontrib><creatorcontrib>Rodeghiero, Francesco</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elice, Francesca</au><au>Raimondi, Roberto</au><au>Tosetto, Alberto</au><au>D'Emilio, Anna</au><au>Di Bona, Eros</au><au>Piccin, Andrea</au><au>Rodeghiero, Francesco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prolonged overall survival with second on‐demand autologous transplant in multiple myeloma</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2006-06</date><risdate>2006</risdate><volume>81</volume><issue>6</issue><spage>426</spage><epage>431</epage><pages>426-431</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><coden>AJHEDD</coden><abstract>Between August 1993 and March 2003, 130 consecutive multiple myeloma (MM) patients eligible for high‐dose treatment were offered a program including up‐front autologous stem cell transplantation (ASCT) after conditioning with 200 mg/m2 melphalan followed by a second ASCT in case of relapse or progression. A total of 107 (82%) patients completed the first ASCT. The best response obtained after ASCT was complete response (CR) 23%, very good partial response (VGPR) 28%, partial response (PR) 42%, and minimal response (MR) 7%. Median overall survival (OS) and event‐free survival (EFS) were 65.4 and 27.7 months, respectively. Relapse or progression occurred in 70 patients; 26 received a second ASCT (with a median time of 20.4 months from first ASCT). A major response (≥PR) was obtained in 69% of these patients. Median OS and EFS after the second ASCT were 38.1 and 14.8 months. Treatment‐related mortality was 1.9% after the first ASCT but no deaths occurred after the second.
Our experience suggests that elective up‐front single ASCT followed by second ASCT after relapse or progression is a safe and effective global strategy to treat MM patients. Am. J. Hematol. 81:426–431, 2006. © 2006 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16680735</pmid><doi>10.1002/ajh.20641</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2006-06, Vol.81 (6), p.426-431 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68039746 |
| source | MEDLINE; Wiley Online Library; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged autologous transplant Biological and medical sciences Disease Progression Disease-Free Survival Female Hematologic and hematopoietic diseases Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Melphalan - administration & dosage Middle Aged Multiple Myeloma - mortality Multiple Myeloma - therapy Myeloablative Agonists - administration & dosage myeloma Recurrence relapse Remission Induction Retrospective Studies Stem Cell Transplantation - mortality Survival Rate Transplantation Conditioning Transplantation, Autologous |
| title | Prolonged overall survival with second on‐demand autologous transplant in multiple myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A30%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prolonged%20overall%20survival%20with%20second%20on%E2%80%90demand%20autologous%20transplant%20in%20multiple%20myeloma&rft.jtitle=American%20journal%20of%20hematology&rft.au=Elice,%20Francesca&rft.date=2006-06&rft.volume=81&rft.issue=6&rft.spage=426&rft.epage=431&rft.pages=426-431&rft.issn=0361-8609&rft.eissn=1096-8652&rft.coden=AJHEDD&rft_id=info:doi/10.1002/ajh.20641&rft_dat=%3Cproquest_cross%3E19738078%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19738078&rft_id=info:pmid/16680735&rfr_iscdi=true |